REVENUE (Tables)

12 Months Ended

Oct. 31, 2025

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:


	Life Sciences and Diagnostics Markets		Agilent CrossLab		Applied Markets		Total
	(in millions)
Year Ended October 31, 2025:
Americas	$	1,337	$	1,095	$	374	$	2,806
Europe	786		811		326		1,923
Asia Pacific	603		1,002		614		2,219
Total	$	2,726	$	2,908	$	1,314	$	6,948

Year Ended October 31, 2024:
Americas	$	1,157	$	1,048	$	368	$	2,573
Europe	723		741		306		1,770
Asia Pacific	586		958		623		2,167
Total	$	2,466	$	2,747	$	1,297	$	6,510

Year Ended October 31, 2023:
Americas	$	1,333	$	1,003	$	396	$	2,732
Europe	729		701		324		1,754
Asia Pacific	718		952		677		2,347
Total	$	2,780	$	2,656	$	1,397	$	6,833

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


		Years Ended October 31,
		2025		2024		2023
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical		$	2,507	$	2,242	$	2,433
Chemicals and Advanced Materials		1,561		1,495		1,543
Diagnostics and Clinical		1,029		964		966
Food		637		592		628
Academia and Government		540		567		601
Environmental and Forensics		674		650		662
Total		$	6,948	$	6,510	$	6,833

Revenue by Type
Instrumentation		$	2,427	$	2,354	$	2,742
Non-instrumentation and other		4,521		4,156		4,091
Total		$	6,948	$	6,510	$	6,833

Contract with Customer, Asset and Liability

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2024 and 2025:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2023	$	616

Net revenue deferred in the period	469
Revenue recognized that was included in the contract liability balance at the beginning of the period	(448)
Change in deferrals from customer cash advances, net of revenue recognized	(9)
Contract liabilities acquired in business combinations	70
Currency translation and other adjustments	3
Ending balance as of October 31, 2024	$	701
Net revenue deferred in the period	564
Revenue recognized that was included in the contract liability balance at the beginning of the period	(476)
Change in deferrals from customer cash advances, net of revenue recognized	7

Currency translation and other adjustments	7
Ending balance as of October 31, 2025	$	803